Post COVID19 Functional and Cognitive Assessments (PostCovidZRS)

September 18, 2022 updated by: Science and Research Centre Koper

Vpliv COVID19 na Izgubo Funkcionalnih zmožnosti Pacientov po zaključenem bolnišničnem Zdravljenju The Effect of COVID19 on the Loss of Functional Capacity of Patients After Hospitalization

The main objective of the proposed study is to evaluate the impact of coronavirus (2019-nCoV), hereafter COVID -19, on patients' loss of functional capacity after completion of hospital treatment. Specifically, the research will focus on examining changes in musculoskeletal, cardiovascular, and respiratory function, as well as motor control. In addition, we aim to evaluate rehabilitation treatments after recovery from COVID -19 and consider additional preventive measures based on previous experience.

Study Overview

Detailed Description

The combination of such a severe respiratory disease as COVID -19 with motor inactivity could have very serious consequences for a person's general health even after COVID -19 symptoms have subsided. To date, the effects of COVID -19 on individual muscle status have not been extensively studied. Therefore, the main objective of this study will be to evaluate the muscle status of patients after COVID -19. In addition, we will be interested in longitudinal monitoring of individuals' rehabilitation, where they will receive instructions based on measured outcomes at hospital discharge. We will also be interested in considering additional preventive measures for future patients based on previous experience of infected and hospitalized COVID -19 patients.

Study Type

Observational

Enrollment (Actual)

43

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All male and female patients who tested positive for COVID -19 and were discharged from hospital care will be enrolled in the study.

Description

Inclusion Criteria:

  • Completed hospital treatment after a positive COVID-19 test
  • Signed written consent

Exclusion Criteria:

  • Still testing positive for COVID -19 at discharge.
  • Severe musculoskeletal injuries (e.g., disability).
  • Inability to follow instructions when performing the test.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Timed up and go test (TUG)
Time Frame: Change in time on TUG between both assessment points (pre- to 2 months post-measurement)
Functional performance of the patients from sitting to standing, walking and turning
Change in time on TUG between both assessment points (pre- to 2 months post-measurement)
Pulse wave velocity (PWV)
Time Frame: Change in PWV between both assessment points (pre- to 2 months post-measurement)
Measuring endothelium function in supine
Change in PWV between both assessment points (pre- to 2 months post-measurement)
Spirometry
Time Frame: Change in FVC (%) between both assessment points (pre- to 2 months post-measurement)
Measurement of lung function, specifically the forced vital capacity (FVC)
Change in FVC (%) between both assessment points (pre- to 2 months post-measurement)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Walking velocity
Time Frame: Change in gait velocity between both assessment points (pre- to 2 months post-measurement)
measurement of gait velocity on the 4m path.
Change in gait velocity between both assessment points (pre- to 2 months post-measurement)
Trail making test B
Time Frame: Change in time to solve the TMT B test between both assessment points (pre- to 2 months post-measurement)
Measurement of executive control using the TMT B test
Change in time to solve the TMT B test between both assessment points (pre- to 2 months post-measurement)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 5, 2021

Primary Completion (Actual)

September 30, 2021

Study Completion (Actual)

September 30, 2021

Study Registration Dates

First Submitted

April 20, 2021

First Submitted That Met QC Criteria

April 21, 2021

First Posted (Actual)

April 26, 2021

Study Record Updates

Last Update Posted (Actual)

September 21, 2022

Last Update Submitted That Met QC Criteria

September 18, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

3
Subscribe